Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Waldenström’s: predicting ibrutinib responses

Steven Treon • 14 Jun 2019
EHA 2019
Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib

Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses data presented at EHA 2019 that investigated predictive factors for long-term response in waldenström’s macroglobulinemia treated with ibrutinib at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Steven Treon

1:59
Updates in the response criteria for Waldenström’s macroglobulinemia
Steven Treon • 29 Sep 2023
2:23
Practical considerations when treating patients with WM: exciting agents & combinations
Steven Treon • 29 Sep 2023
1:54
Selecting the correct BTK inhibitor for patients with WM: lessons learned from the ASPEN trial
Steven Treon • 29 Sep 2023
1:47
Exciting updates in Waldenström’s macroglobulinemia: the value of BTK inhibitors
Steven Treon • 29 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals